Johanna M. Mylet's most recent trade in Poseida Therapeutics Inc was a trade of 254,852 Common Stock done . Disclosure was reported to the exchange on Jan. 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | 08 Jan 2025 | 254,852 | 0 | - | - | Common Stock | ||
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 125,283 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 111,700 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 82,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 80,192 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 72,568 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 65,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 35,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 4,117 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 111,700 | 111,700 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 80,743 | 264,374 | - | 0 | Common Stock | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.13 per share. | 01 Mar 2024 | 18,091 | 246,283 | - | 4.1 | 74,716 | Common Stock |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 125,283 | 125,283 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 92,772 | 181,954 | - | 0 | Common Stock | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.35 per share. | 01 Mar 2023 | 4,323 | 177,631 | - | 5.3 | 23,128 | Common Stock |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 72,568 | 72,568 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 50,000 | 84,231 | - | 0 | Common Stock | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 3,100 | 3,816 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 21 Dec 2021 | 3,100 | 34,231 | - | 1.9 | 5,992 | Common Stock |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 2,616 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.17 per share. | 21 Dec 2021 | 2,616 | 31,131 | - | 1.2 | 3,069 | Common Stock |
| Poseida Therapeutics Inc | Johanna M. Mylet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 65,000 | 65,000 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Senior Vice President, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 82,000 | 82,000 | - | - | Employee Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 15 Jan 2021 | 4,728 | 26,813 | - | 0.3 | 1,418 | Common Stock |
| Poseida Therapeutics Inc | Johanna M. Mylet | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 4,177 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Johanna M. Mylet | Senior Vice President, Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 551 | 0 | - | - | Stock Option (Right to Buy) |